Global Market Opportunities and Competitive Landscape for CDMO

Report Highlights

The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.

Report Includes

• 76 data tables and 32 additional tables
• An overview of the global contract development and manufacturing organization (CDMO) market
• Analysis of the global market trends, with data from 2021-2022, estimates for 2023, forecast for 2024, and projections of compound annual growth rates (CAGRs) through 2029
• Estimates of the market size and revenue forecast for the CDMO market, and a corresponding market share analysis based on type of service, drug molecule type, end user, and region
• Evaluation of the market potential and opportunities for pharmaceutical CDMOs, regulatory policies, standards and inspection trends
• Identifying the pharma companies that are considered leaders in their field, as well as the technological means these companies are using to exploit their markets
• A look at the competitive landscape of the global CDMO market, featuring companies contracting with a contract manufacturing outsourcer for both clinical and commercial stage manufacturing
• A discussion of the ESG challenges and practices in the CDMO industry
• An analysis of the market shares of key companies in the industry as well as their proprietary technologies and strategic alliances
• Profiles of the leading players, including Thermo Fisher Scientific Inc., Merck KGaA, Lonza, Catalent Inc., and WuXi AppTec

Report Scope

This report provides an overview of the pharmaceutical business and the function of contract development and manufacturing organizations (CDMOs). The analysis includes a review of the global CDMO market by service type, drug molecule type and end use. It also examines the regulatory policies, standards and inspection trends of the global CDMO markets. In addition, the competitive environment, significant rivals, significant leaders and top 10 manufacturers in the CDMO sector are also reviewed.

The report presents a detailed description of the service types (API manufacturing services, drug product/finished drug manufacturing service, pharmaceutical development services and analytical testing and regulatory support services) and current and historical market revenues. The CDMO markets are also segmented based on type of molecule (small-molecule drugs, biologics and advanced therapies) and end user (clinical and commercial). The market revenue for each geographic segment (North America, Europe, Asia-Pacific and the Rest of the World) has also been provided in the report.

In order to provide an in-depth understanding of the market, profiles of market participants, competitive landscape, key competitors and respective market share are also included in this report. For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.